The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of FCN-159, a MEK1/2 inhibitor in pediatric participants with neurofibromatosis type 1: Results from a phase 2 trial.
 
JinHu Wang
No Relationships to Disclose
 
Wenbin Li
No Relationships to Disclose
 
Kang Zeng
No Relationships to Disclose
 
Xiaoxi Lin
No Relationships to Disclose
 
Yanling Li
No Relationships to Disclose
 
Zhonghai Guan
No Relationships to Disclose
 
Zhuang Kang
No Relationships to Disclose
 
Changxing Li
No Relationships to Disclose
 
Xiaojie Hu
No Relationships to Disclose
 
Yaohui Ma
No Relationships to Disclose
 
Zhuli Wu
No Relationships to Disclose
 
Xingli Wang
No Relationships to Disclose
 
Pu Han
No Relationships to Disclose
 
Hongmei Lin
No Relationships to Disclose
 
Wen Zhong
No Relationships to Disclose